Skip to main content

Table 2 Efficacy of telbivudine treatment

From: Telbivudine can safely reduce mother-to-child transmission in chronic hepatitis B women after 12 weeks of gestation

  Telbivudine
(N = 139)
Control
(N = 102)
P value
HBV DNA, log10 IU/mL, median (range)
 Week 2 5.51 (3.04–8.06) 7.74 (6.03–9.00) < 0.001
 Week 4 4.12 (2.70–7.43) 7.70 (6.03–9.00) < 0.001
 Week 8 3.20 (2.70–6.76) 7.74 (6.03–9.00) < 0.001
 At delivery 2.82 (2.70–6.45) 7.72 (5.32–9.00) < 0.001
ALT levels at delivery, U/L, median (range) 28 (11–238) 47 (8–217) < 0.001
Normalization rate of ALT, n (%) 105 (75.5%) 52 (51%) < 0.001
AST levels at delivery, U/L, median (range) 27 (11–141) 39 (17–144) < 0.001
Normalization rate of AST, n (%) 112 (80.6%) 55 (53.9%) < 0.001
TBIL levels at delivery, U/L, median (range) 1.1 (9.8–36.0) 9.5 (3.8–48.6) 0.459
Normalization rate of TBIL, n (%) 137 (98.6%) 100 (98.0%) 1.000
HBeAg positive at delivery, n (%) 108 (77.7%) 91 (89.2%) 0.025